... ) or interstitial lung disease, WHO group 4 is related to chronic thromboembolic pulmonary hypertension ...
... , and WHO group 5 is pulmonary hypertension associated to multifactorial causes (Gali et al., 2016 ...
... ). Pulmonary COVID-19 AND PAH 4 arterial hypertension, WHO Group 1 (PAH), can be the result of idiopathic or ...
... type 5 inhibitors and/or guanylate cyclase stimulators (Gail et al., 2016). PAH treatment can consist ...
... AND PAH 5 comorbidities and the elderly, when infected with COVID-19, are extremely susceptible to ...